Stock listing
NASDAQ:XLO Xilio Therapeutics, Inc. Stock
Home listing (NASDAQ) of Xilio Therapeutics, Inc.
Follow Xilio Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:XLO
$7.56 USD -0.07 (-0.9%)
Close on Nov 20, 2026
- Day range
- $7.07 – $7.60 USDNov 20, 2026
- Volume
- 20,100 sharesNov 20, 2026
- Market cap
- $53.40M USDAt the close on Nov 20, 2026 · price × 7.06M shares outstanding
- 52-week range
- $6.47 – $10.71 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $98,525 USDMedian day 9,000 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:XLO · Home | $7.56 USD | -0.07 (-0.9%) | 20,100 | $7.60 | $7.60 | $7.065 | $7.63 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:XLO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $7.56 | -0.07 | -0.9% | $7.60 | $7.60 | $7.065 | 20,100 | |
| $7.63 | +0.09 | +1.2% | $7.879 | $7.94 | $7.25 | 8,083 | |
| $7.54 | -0.16 | -2.1% | $7.805 | $7.837 | $7.14 | 6,147 | |
| $7.70 | -0.375 | -4.6% | $7.87 | $8.44 | $7.10 | 8,377 | |
| $8.075 | -0.165 | -2.0% | $7.96 | $8.075 | $7.85 | 7,515 | |
| $8.24 | -0.23 | -2.7% | $8.25 | $8.25 | $7.96 | 9,084 | |
| $8.47 | -0.06 | -0.7% | $8.82 | $8.82 | $8.405 | 3,528 | |
| $8.53 | -0.47 | -5.2% | $8.53 | $8.53 | $8.53 | 3,078 | |
| $9.00 | +0.38 | +4.4% | $8.857 | $9.00 | $8.57 | 10,623 | |
| $8.62 | +0.12 | +1.4% | $8.24 | $8.69 | $8.24 | 6,639 | |
| $8.50 | -0.21 | -2.4% | $8.45 | $8.65 | $7.775 | 26,839 | |
| $8.71 | +0.03 | +0.3% | $8.425 | $8.86 | $8.425 | 11,854 | |
| $8.68 | +0.69 | +8.6% | $8.03 | $8.85 | $7.935 | 24,451 | |
| $7.99 | -0.04 | -0.5% | $7.49 | $8.065 | $7.49 | 6,802 | |
| $8.03 | +0.26 | +3.3% | $7.05 | $8.089 | $7.05 | 7,720 | |
| $7.77 | -0.24 | -3.0% | $7.93 | $7.93 | $7.77 | 2,588 | |
| $8.01 | 0.00 | 0.0% | $7.81 | $8.19 | $7.57 | 16,674 | |
| $8.01 | +0.70 | +9.6% | $7.855 | $8.01 | $7.17 | 27,920 | |
| $7.31 | -0.26 | -3.4% | $7.54 | $8.637 | $7.05 | 33,066 | |
| $7.57 | -0.46 | -5.7% | $8.06 | $8.245 | $7.51 | 16,300 | |
| $8.03 | -0.40 | -4.7% | $8.45 | $8.48 | $8.00 | 15,400 | |
| $8.43 | -0.11 | -1.3% | $8.545 | $9.05 | $8.249 | 36,300 | |
| $8.54 | +0.21 | +2.5% | $8.25 | $8.84 | $8.25 | 13,500 | |
| $8.33 | -0.22 | -2.6% | $8.69 | $8.735 | $8.33 | 11,500 | |
| $8.55 | -0.47 | -5.2% | $8.91 | $9.00 | $8.55 | 29,600 | |
| $9.02 | +0.12 | +1.3% | $8.88 | $9.38 | $8.88 | 10,400 | |
| $8.90 | -0.32 | -3.5% | $9.08 | $9.08 | $8.772 | 12,400 | |
| $9.22 | +0.145 | +1.6% | $9.05 | $9.22 | $8.855 | 18,100 | |
| $9.075 | +0.025 | +0.3% | $9.11 | $9.42 | $8.982 | 8,400 | |
| $9.05 | +0.04 | +0.4% | $8.94 | $9.16 | $8.82 | 5,500 | |
| $9.01 | 0.00 | 0.0% | $9.01 | $9.14 | $8.775 | 20,800 | |
| $9.01 | +0.01 | +0.1% | $9.00 | $9.01 | $9.00 | 900 | |
| $9.00 | -0.11 | -1.2% | $9.10 | $9.32 | $8.81 | 6,200 | |
| $9.11 | +0.10 | +1.1% | $9.07 | $9.49 | $9.07 | 7,200 | |
| $9.01 | +0.10 | +1.1% | $8.89 | $9.075 | $8.89 | 7,400 | |
| $8.91 | -0.14 | -1.5% | $8.97 | $9.12 | $8.79 | 12,900 | |
| $9.05 | +0.112 | +1.3% | $9.19 | $9.25 | $9.05 | 5,400 | |
| $8.938 | -0.112 | -1.2% | $9.568 | $9.568 | $8.938 | 3,100 | |
| $9.05 | +0.01 | +0.1% | $9.21 | $9.22 | $8.96 | 11,100 | |
| $9.04 | +0.04 | +0.4% | $9.00 | $9.21 | $8.93 | 3,400 | |
| $9.00 | +0.06 | +0.7% | $8.93 | $9.09 | $8.93 | 16,000 | |
| $8.94 | -0.10 | -1.1% | $9.03 | $9.04 | $8.94 | 1,300 | |
| $9.04 | +0.02 | +0.2% | $9.04 | $9.16 | $8.95 | 6,900 | |
| $9.02 | -0.11 | -1.2% | $8.96 | $9.175 | $8.96 | 7,100 | |
| $9.13 | +0.09 | +1.0% | $8.995 | $9.67 | $8.94 | 22,900 | |
| $9.04 | +0.06 | +0.7% | $9.00 | $9.049 | $8.93 | 14,500 | |
| $8.98 | -0.05 | -0.6% | $9.02 | $9.02 | $8.93 | 11,500 | |
| $9.03 | +0.10 | +1.1% | $8.93 | $9.03 | $8.93 | 17,300 | |
| $8.93 | 0.00 | 0.0% | $9.06 | $9.21 | $8.93 | 10,300 | |
| $8.93 | 0.00 | 0.0% | $8.93 | $9.49 | $8.93 | 5,100 | |
| $8.93 | -0.04 | -0.4% | $8.95 | $9.00 | $8.93 | 11,800 | |
| $8.97 | +0.06 | +0.7% | $8.91 | $9.00 | $8.80 | 9,000 | |
| $8.91 | -0.09 | -1.0% | $9.03 | $9.11 | $8.81 | 10,000 | |
| $9.00 | -0.02 | -0.2% | $9.231 | $9.231 | $8.81 | 7,600 | |
| $9.02 | +0.18 | +2.0% | $8.94 | $9.10 | $8.721 | 6,600 | |
| $8.84 | -0.04 | -0.5% | $9.142 | $9.142 | $8.84 | 4,700 | |
| $8.88 | -0.07 | -0.8% | $8.57 | $9.248 | $8.57 | 31,100 | |
| $8.95 | -0.05 | -0.6% | $9.00 | $9.27 | $8.90 | 14,600 | |
| $9.00 | -0.01 | -0.1% | $8.995 | $9.28 | $8.995 | 3,600 | |
| $9.01 | -0.04 | -0.4% | $8.785 | $9.115 | $8.785 | 9,000 | |
| $9.05 | -0.03 | -0.3% | $9.09 | $9.145 | $8.922 | 7,700 | |
| $9.08 | -0.11 | -1.2% | $9.16 | $9.30 | $9.08 | 5,895 | |
| $9.19 | -0.04 | -0.4% | $9.32 | $9.32 | $9.17 | 2,293 | |
| $9.23 | 0.00 | 0.0% | $9.21 | $9.23 | $9.07 | 5,200 | |
| $9.23 | -0.18 | -1.9% | $9.27 | $9.27 | $9.11 | 6,400 |
Splits
1 split · NASDAQ:XLO · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-14 | Consolidation |
- Ticker
- NASDAQ:XLO
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 10, 2026
Xilio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Pipeline and Business Updates
Latest deck · Mar 9, 2026
Investor Presentation (March 2026)
Investor deck · 36 slides
Latest news
Xilio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Pipeline and Business Updates
Nov 10, 2026
Closed $8.53 (-5.2%) on Nov 10, 2026
Xilio Therapeutics to Present at the Stifel 2026 Healthcare Conference
Nov 3, 2026
Closed $8.71 (+0.3%) on Nov 4, 2026
Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLC
Oct 26, 2026
Closed $7.31 (-3.4%) on Oct 26, 2026
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 2, 2026
Closed $9.11 (+1.1%) on Oct 5, 2026
Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer
Sep 28, 2026
Closed $9.05 (+0.1%) on Sep 28, 2026
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
Aug 12, 2026
Closed $9.05 (-1.4%) on Aug 12, 2026
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
Jun 29, 2026
Closed $9.27 (+2.4%) on Jun 29, 2026
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
May 12, 2026
Closed $7.73 (0.0%) on May 12, 2026
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 7, 2026
May 11, 2026
Closed $7.73 (-0.1%) on May 11, 2026
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
Apr 17, 2026
Closed $8.45 (-1.4%) on Apr 20, 2026
Xilio Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 18 in the last 12 months · 71 in all · newest Nov 10, 2026 · oldest 2021
- Decks
- 11 decks · latest Mar 9, 2026
Where Xilio Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:XLO · Home listing · This page | NASDAQ | United States | USD |
| BOATS:XLO | BOATS | United States | USD |
Valuation
EV/sales −1.1× against a median of 248×: the lowest of 4 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$62.82M USD
- P/E
- Loss
- EV/sales
- −1.1×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.8×
- Gross margin
- 99.4%
- Operating margin
- −74.9%
- Net margin
- −20.9%
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 0.76
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Xilio Therapeutics, Inc. · NASDAQ:XLO | US$53.40M | −US$62.82M | n/a | −1.1× | n/a | 0.8× | −20.9% | 0.1× | 0.76 |
| Cognition Therapeutics, Inc. · NASDAQ:CGTX | US$55.37M | US$25.10M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | 2.28 |
| AB Science SA · EURONEXT:AB | US$55.19M | US$50.54M | n/a | 39.2× | n/a | n/a | −132.6% | n/a | n/a |
| Azora Therapeutics, Inc. · NASDAQ:AZR | US$55.00M | US$33.00M | n/a | n/a | n/a | n/a | n/a | n/a | 1.00 |
| Island Pharmaceuticals Ltd · ASX:ILA | US$54.84M | US$46.32M | n/a | 248× | n/a | 6.2× | n/a | 0.0× | n/a |
| Anavex Life Sciences Corp. · NASDAQ:AVXL | US$54.83M | −US$63.50M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 2.39 |
| Nordicus Partners Corp · OTC:NORD | US$54.44M | US$54.44M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.45 |
| Boundless Bio, Inc. · NASDAQ:BOLD | US$53.61M | −US$9.28M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.65 |
| Impact BioMedical, Inc. · AMEX:IBO | US$53.31M | US$53.29M | 33.0× | 1,402× | n/a | 5.3× | n/a | 0.0× | 0.06 |
| XBiotech Inc. · NASDAQ:XBIT | US$52.74M | −US$52.29M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | 0.52 |
| Bonus Biogroup Ltd. · TASE:BONS | US$52.22M | US$54.52M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Median of the others | US$54.64M | US$39.66M | 33.0× | 248× | 0.9× | −132.6% | 0.0× | 0.65 |
Forecasts
1 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 18.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.95 · 1 analyst
- Revenue, year to Dec 2026
- 45.32M · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| René Russo | President and Chief Executive Officer |
| Chris Frankenfield | Chief Financial and Operating Officer |
| Ben Harshbarger | Chief Legal Officer |
| Nathan McBride | Chief Information Officer |
| Scott Coleman | Chief Development Officer |
| Uli Bialucha | Chief Scientific Officer |
| Yariv Houvras | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Sara Bonstein | Chair of the Board |
| Akintunde Bello | Board Member |
| Aoife Brennan | Board Member |
| Cheryl R. Blanchard | Board Member |
| Daniel Curran | Board Member |
| James Shannon | Board Member |
| René Russo | President and Chief Executive Officer |
| Robert Ross | Board Member |
| Yuan Xu | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · Before open | −5.2% |
| Q2 2026 | Aug 12, 2026 · Before open | −1.4% |
| Q1 2026 | May 12, 2026 | +0.4% |
| Q4 2025 | Mar 4, 2026 | +2.5% |
| Q3 2025 | Nov 13, 2025 · Before open | −9.2% |
| Q2 2025 | Aug 14, 2025 · Before open | −1.7% |
| Q1 2025 | May 8, 2025 · Before open | +8.0% |
| Q4 2024 | Mar 11, 2025 | −2.4% |
| Q3 2024 | Nov 7, 2024 · Before open | −19.4% |
| Q2 2024 | Aug 8, 2024 · Before open | −0.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Apr 1, 2024 · After close | −3.3% |
| Q4 2023 | Feb 7, 2024 · After close | −8.5% |
| Q3 2023 | Nov 9, 2023 · After close | −10.6% |
| Q2 2023 | Aug 14, 2023 · Before open | +2.1% |
| Q1 2023 | May 9, 2023 · Before open | +2.1% |
| Q4 2022 | Mar 2, 2023 · After close | +2.9% |
| Q3 2022 | Nov 9, 2022 · Before open | −1.0% |
| Q2 2022 | Aug 9, 2022 · Before open | −26.2% |
| Q1 2022 | May 12, 2022 · Before open | −2.6% |
| Q4 2021 | Mar 1, 2022 · Before open | −7.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (March 2026) | Investor deck | 36 slides | Mar 9, 2026 |
| Investor Presentation (June 2025) | Investor deck | 44 slides | Jun 2, 2025 |
| Investor Presentation (January 2025) | Investor deck | 43 slides | Jan 21, 2025 |
| Investor Presentation (December 2024) | Investor deck | 42 slides | Dec 19, 2024 |
| Q3 2024 Earnings Presentation | Earnings | 50 slides | Nov 7, 2024 |
| Q2 2023 Earnings Presentation | Earnings | 52 slides | Aug 14, 2023 |
| Corporate Update (May 2023) | Corporate update | 54 slides | May 25, 2023 |
| Investor Presentation (January 2023) | Investor deck | 39 slides | Jan 9, 2023 |
| Q3 2022 Earnings Presentation | Earnings | 37 slides | Nov 9, 2022 |
| Q1 2022 Earnings Presentation | Earnings | 34 slides | May 12, 2022 |
All 11 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| 2021 Next-Gen Cytokines Summit | Conference | 27 slides | Sep 22, 2021 |
Financings
| Raise | Date |
|---|---|
| Public offering of pre-funded warrants Announced: about US$40M · US$0.5349 a share · Warrants at US$0.0001 · Leerink Partners Dealers: Leerink Partners (lead) Buyers: Coastlands Capital (led the financing; existing investor); Gilead Sciences, Inc.; OrbiMed; Perceptive Advisors Use of proceeds: Advance development of product candidates, working capital and general corporate purposes | Feb 12, 2026 |
| Public offering of pre-funded warrants accompanied by Series A, Series B and Series C warrants Closed: US$50M raised · US$0.7499 a share · Warrants at US$0.75 · Leerink Partners Dealers: Leerink Partners (lead) Buyers: Coastlands Capital; Frazier Life Sciences; Gilead Sciences, Inc.; Logos Capital; Samsara BioCapital Use of proceeds: Advance development of product candidates, working capital and general corporate purposes | Jun 5, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$16.00 a share on Oct 21, 2021.
- Price
- US$16.00 a share
- Shares offered
- 7,353,000 shares of common stock
- Offering size
- US$117.6 million
- Underwriters' option
- Up to 1,102,950 more shares
- Listing
- XLO on the Nasdaq Global Select Market
- Underwriters
- MORGAN STANLEY, COWEN, GUGGENHEIM SECURITIES, RAYMOND JAMES · In the order on the cover
- Shares delivered
- On or about Oct 26, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 24, 2021 |
| Filed publicly | Oct 1, 2021 |
| Amended twice | Newest Oct 20, 2021 |
| Shares registered with an exchange | Oct 18, 2021 |
| Declared effective by the SEC | Oct 21, 2021 |
| Final prospectus, with the price | Oct 22, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 22, 2021 |
| EFFECT · Notice that a registration is effective | Oct 21, 2021 |
| CERT · Exchange's certificate of listing | Oct 21, 2021 |
| S-1/A · Registration statement, amended | Oct 20, 2021 |
| CORRESP · Letter to the SEC | Oct 19, 2021 |
| CORRESP · Letter to the SEC | Oct 19, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 18, 2021 |
| CORRESP · Letter to the SEC | Oct 18, 2021 |
| S-1/A · Registration statement, amended | Oct 18, 2021 |
| UPLOAD · Letter from the SEC | Oct 13, 2021 |
All 17 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Oct 1, 2021 |
| S-1 · Registration statement | Oct 1, 2021 |
| UPLOAD · Letter from the SEC | Sep 23, 2021 |
| DRSLTR · Letter to the SEC with a draft | Sep 14, 2021 |
| DRS/A · Draft registration statement, amended | Sep 14, 2021 |
| UPLOAD · Letter from the SEC | Jun 21, 2021 |
| DRS · Draft registration statement | May 24, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 22, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 43.8M | 6.34M | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 1.54M | 1.64M | 1.90M | 1.85M | 1.50M | 1.06M | 240.0K |
| Gross profit | 42.2M | 6.34M | -1.90M | -1.85M | -1.50M | -1.06M | -240.0K |
| Research and development | 56.0M | 41.2M | 52.1M | 59.2M | 51.2M | 43.9M | 14.3M |
| Selling, general and administrative | 29.7M | 24.8M | 27.0M | 29.9M | 23.9M | 10.7M | 4.77M |
| Operating income | -42.0M | -60.6M | -79.1M | -89.1M | -75.0M | -54.6M | -19.0M |
| Depreciation and amortization | 1.54M | 1.64M | 1.90M | 1.85M | 1.50M | 1.06M | 240.0K |
| EBITDA | -40.4M | -58.9M | -77.2M | -87.3M | -73.5M | -53.5M | -18.8M |
| Interest expense | 100.0K | 127.8K | 927.0K | 756.0K | 600.0K | 0 | |
| Income before tax | -35.0M | -58.2M | -76.4M | -88.2M | -75.8M | -55.2M | -17.3M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 68.1K |
| Net income | -35.0M | -58.2M | -76.4M | -88.2M | -75.8M | -55.2M | -17.3M |
| Earnings per share, basic | -4.19 | -15.24 | -2.78 | -3.22 | -13.52 | -105.42 | -592.11 |
| Earnings per share, diluted | -4.19 | -15.24 | -2.78 | -3.22 | -13.52 | -105.42 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 137.5M | 55.3M | 44.7M | 120.4M | 198.1M | 19.2M | 48.8M |
| Receivables | 5.00M | 267.0K | 393.0K | ||||
| Current assets | 145.0M | 60.2M | 48.1M | 124.5M | 202.5M | 20.6M | 51.1M |
| Property, plant and equipment | 3.89M | 4.47M | 5.94M | 7.25M | 7.62M | 7.37M | 9.87M |
| Total assets | 154.7M | 71.1M | 60.9M | 139.2M | 218.1M | 36.3M | 62.7M |
| Accounts payable | 3.17M | 2.57M | 1.05M | 3.13M | 3.14M | 5.44M | 2.52M |
| Current liabilities | 56.3M | 27.3M | 16.0M | 21.1M | 12.8M | 22.2M | 5.21M |
| Long-term debt | 3.17M | 9.63M | 7.41M | 9.61M | |||
| Total debt | 6.95M | 8.14M | 12.5M | 19.9M | 20.7M | 21.9M | 18.6M |
| Total liabilities | 119.4M | 53.5M | 24.1M | 33.5M | 32.6M | 41.6M | 24.2M |
| Shareholders' equity | 35.3M | 17.6M | 36.8M | 105.6M | 185.4M | -83.3M | 38.5M |
| Shares outstanding | 4.53M | 3.27M | 27.6M | 27.4M | 27.4M | 689.9K | 29.2K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -4.99M | -18.4M | -68.6M | -75.7M | -80.8M | -36.1M | -17.8M |
| Capital spending | -518.0K | -36.0K | -486.0K | -1.87M | -1.10M | -2.19M | -715.0K |
| Free cash flow | -5.51M | -18.4M | -69.1M | -77.6M | -81.9M | -38.3M | -18.6M |
| Cash from investing | -518.0K | -36.0K | -486.0K | -1.87M | -1.10M | -2.19M | -715.0K |
| Cash from financing | 87.8M | 29.2M | -6.55M | -69.0K | 260.7M | 10.0M | 60.0M |
| Share buybacks | 2.81M | 194.0K | 16.0K | 261.5M | |||
| Change in cash | 82.3M | 10.8M | -75.7M | -77.7M | 178.8M | -28.3M | 41.5M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 12, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Nov 10, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 2, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| S-8 · Registration statement for employee plans | Aug 12, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2026 | Results | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 12, 2026 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Jun 1, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 27, 2026 | Other filings | SEC |
| S-3/A · Registration statement, amended | May 27, 2026 | Offer document | SEC |
| UPLOAD · Letter from the SEC | May 18, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| S-3 · Registration statement | May 12, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 28, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 28, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 16, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 16, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 16, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Mar 30, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 23, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 23, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 23, 2026 | Results | SEC |
| 8-K · Current report | Mar 12, 2026 | Current report | SEC |
| 8-K · Current report | Mar 9, 2026 | Current report | SEC |
| 8-K · Current report | Feb 24, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 12, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Feb 12, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2026 | Big-stake notice | SEC |
| 424B5 · Prospectus | Feb 11, 2026 | Offer document | SEC |
| DEF 14A · Proxy statement | Jan 26, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Jan 16, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jan 8, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 5, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 11, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Nov 25, 2025 | Offer document | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 25, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| 8-K · Current report | Nov 7, 2025 | Current report | SEC |
| DEF 14A · Proxy statement | Oct 20, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Oct 10, 2025 | Meeting notice | SEC |
| 8-K · Current report | Oct 3, 2025 | Current report | SEC |
| 8-K · Current report | Sep 9, 2025 | Current report | SEC |
| 8-K · Current report | Aug 28, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 18, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 17, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 12, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 12, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Jun 10, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Jun 3, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jun 3, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jun 3, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Jun 2, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 2, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | May 9, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| CORRESP · Letter to the SEC | May 6, 2025 | Other filings | SEC |
| S-3/A · Registration statement, amended | May 6, 2025 | Offer document | SEC |
| ARS · Annual report to shareholders | Apr 28, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 18, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 8, 2025 | Current report | SEC |
| UPLOAD · Letter from the SEC | Mar 17, 2025 | Other filings | SEC |
| S-3 · Registration statement | Mar 11, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 11, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Mar 11, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 11, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 11, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 11, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 18, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 12, 2025 | Material contract | SEC |
| 8-K · Current report | Jan 21, 2025 | Current report | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2024 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 19, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Dec 19, 2024 | Financing | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Sep 27, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Sep 27, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 13, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 4 · Change in ownership | Aug 6, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Jul 31, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 17, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 17, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Jun 13, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2024 | Results | SEC |
| EFFECT · Notice that a registration is effective | May 7, 2024 | Other filings | SEC |
| 4 · Change in ownership | May 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 3, 2024 | Insider trade | SEC |
| CORRESP · Letter to the SEC | May 2, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 2, 2024 | Other filings | SEC |
| S-3 · Registration statement | Apr 30, 2024 | Offer document | SEC |
| ARS · Annual report to shareholders | Apr 25, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2024 | Meeting notice | SEC |
| 424B5 · Prospectus | Apr 15, 2024 | Offer document | SEC |
| SC 13G · Big-stake notice | Apr 5, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Apr 5, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 3, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 3, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Apr 1, 2024 | Offer document | SEC |
| 10-K · Annual report | Apr 1, 2024 | Annual report | SEC |
| 8-K · Current report | Apr 1, 2024 | Results | SEC |
| 8-K · Current report | Mar 28, 2024 | Current report | SEC |
| 8-K · Current report | Mar 28, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 9, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 6, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 5, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jan 19, 2024 | Current report | SEC |
| 4 · Change in ownership | Jan 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 3, 2024 | Management or board change | SEC |
| 8-K · Current report | Dec 7, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2023 | Results | SEC |
| 10-Q/A · Quarterly report, amended | Nov 9, 2023 | Quarterly report | SEC |
| 10-Q/A · Quarterly report, amended | Nov 9, 2023 | Quarterly report | SEC |
This page holds 200 of 364 filings. Open Filings
Cap table
Built by 6ix from Xilio Therapeutics, Inc.’s releases · as of Nov 6, 2026
- Common shares
- 7,063,982
- Fully diluted
- 7,063,982
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 7,063,982 | Nov 6, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$0.75 · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 6, 2026 | 7,063,982 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Cheryl R. Blanchard Other companies: Vigil Neuroscience Inc (Director · Since at least Jan 6, 2022); Anika Therapeutics Inc. (Director · Since at least Aug 31, 2018); Dare Bioscience, Inc. (Director · Nov 20, 2019 – Jun 21, 2023 · Past); Neuronetics, Inc. (Director · Feb 13, 2019 – May 26, 2020 · Past); SeaSpine Holdings Corp (Director · Jul 1, 2015 – May 30, 2018 · Past); Zimmer Biomet Holdings, Inc. (Sr. VP, Chief Scientific Off. · Feb 17, 2011 – Mar 19, 2012 · Past) | Board Member · Since at least Apr 15, 2026 |
| James Shannon Other companies: ProQR Therapeutics N.V. (Director · Since at least Mar 18, 2026); MannKind Corporation (Chairman of the Board · Since at least Jun 10, 2010); Horizon Pharma PLC (Director · Aug 2, 2017 – Aug 2, 2018 · Past); Endocyte Inc (Director · Feb 4, 2011 – May 26, 2011 · Past) | Board Member · Since at least Jun 13, 2024 |
| Aoife Brennan Other companies: Climb Bio, Inc. (President and CEO, Director · Since at least Jun 27, 2024); Kyntra Bio, Inc. (Director · May 26, 2021 – Jun 5, 2024 · Past); Synlogic Inc (President and CEO, Director · Mar 10, 2021 – Nov 10, 2023 · Past) | Director · Since at least Jun 13, 2024 |
| Martin H Huber Jr Other companies: Actuate Therapeutics, Inc. (Director · Since at least May 1, 2026); Syndax Pharmaceuticals, Inc. (Director · Since at least Sep 15, 2021); Mersana Therapeutics Inc (President, CEO, Director · Since at least Jan 15, 2021) | PRESIDENT AND HEAD OF R&D · Oct 21, 2021 – Aug 16, 2023 · Past |
| Sara Bonstein Other companies: Latigo Biotherapeutics, Inc. (Director · Since at least Aug 6, 2026); Scpharmaceuticals Inc (Director · Since at least Jun 14, 2022); Insmed Incorporated (Chief Financial Officer · Since at least May 11, 2022) | Chair of the Board · Since at least Jun 15, 2022 |
| Christina Rossi Other companies: CG Oncology, Inc. (Biopharmaceutical Executive & Board Member · Since at least Nov 24, 2025); Blueprint Medicines Corp (Chief Operating Officer · Since at least Oct 29, 2018) | Director · Since at least Oct 21, 2021 |
| Daniel J. Curran Other companies: ALX Oncology Holdings Inc. (Director · Since at least Aug 12, 2025); Catalyst Pharmaceuticals, Inc. (Director · Since at least Aug 1, 2025) | Board Member · Since at least Oct 21, 2021 |
| Rachel Humphrey Other companies: Pyxis Oncology, Inc. (Director · Since at least Aug 11, 2022); Black Diamond Therapeutics, Inc. (Chief Medical Officer · Feb 17, 2021 – Feb 17, 2021 · Past) | Director · Oct 21, 2021 – Oct 21, 2021 · Past |
| René Russo Other companies: Invivyd, Inc. (Director · Aug 5, 2021 – Aug 5, 2021 · Past); X4 Pharmaceuticals, Inc. (Director · Jun 17, 2019 – Jun 2, 2021 · Past) | President and Chief Executive Officer · Since at least Oct 21, 2021 |
| Yuan Xu Other companies: Fate Therapeutics, Inc. (Director · Since at least Aug 3, 2021); Akero Therapeutics Inc (Director · Since at least Apr 22, 2021) | Director · Since at least Jan 4, 2022 |
All 22 people
| Person | Seat |
|---|---|
| Robert Ross Other companies: Obsidian Therapeutics, Inc. (Director · Since at least Aug 3, 2026) | Board Member · Since at least Jun 14, 2024 |
| Akintunde Bello | Board Member · Since at least Jun 10, 2025 |
| Ben Harshbarger | Chief Legal Officer · Since at least Jun 29, 2026 |
| Caroline Hensley | Chief Legal Officer · Dec 16, 2024 – Nov 4, 2026 · Past |
| Chris Frankenfield | Chief Financial and Operating Officer · Since at least Nov 4, 2026 |
| ContactScott Young | Vice President, Investor Relations and Corporate Communications · Feb 12, 2025 – Nov 4, 2026 · Past |
| Katarina Luptakova | CHIEF MEDICAL OFFICER · Since at least Sep 5, 2023 |
| Nathan McBride | Chief Information Officer · Since at least Nov 4, 2026 |
| Scott Coleman | Chief Development Officer · Since at least Nov 4, 2026 |
| Uli Bialucha | Chief Scientific Officer · Since at least Apr 17, 2026 |
| Yariv J. Houvras | Chief Medical Officer · Since at least Sep 28, 2026 |
| Yuan Xu | Board Member · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Xilio Therapeutics, Inc.